Presentation is loading. Please wait.

Presentation is loading. Please wait.

Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand D-optimal Adaptive Bridging Studies in Pharmacokinetics Lee-Kien Foo.

Published byCori Hancock Modified over 8 years ago

Similar presentations

Presentation on theme: "Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand D-optimal Adaptive Bridging Studies in Pharmacokinetics Lee-Kien Foo."— Presentation transcript:

1 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand D-optimal Adaptive Bridging Studies in Pharmacokinetics Lee-Kien Foo Stephen Duffull Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand

2 Bridging Studies A concept for extrapolating information gathered from a clinical study in an original region to a new region One of the purposes is to assess the dose exposure relationship in the new region

3 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Optimal Adaptive Design Collect data Fit a model Optimize design Initial design Refine design

4 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Aim To develop an optimal adaptive design method for bridging studies (D-optimal ABS) that can be applied to pharmacokinetics

5 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand This Talk D-optimal ABS Simulation studies Results Discussion

6 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand D-optimal ABS Information from a prior population Adaptive D-optimal design Combine information in the process Learn about the target population

7 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand D-optimal ABS Fit the model D-optimal design Initial design Collect data from prior population

8 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand D-optimal ABS Fit the model D-optimal design Initial design Collect batch data from target population Collect data from prior population

9 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand D-optimal ABS Reduce data proportionally Pool data Fit the model D-optimal design Initial design Collect batch data from target population Collect data from prior population

10 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand D-optimal ABS Reduce data proportionally Pool data Fit the model D-optimal design Initial design Collect batch data from target population Collect data from prior population

11 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand D-optimal ABS Iteration b –Estimation: –Population Fisher information matrix:

12 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Studies Simulation studies were performed for two different scenarios Carried out in MATLAB and NONMEM, called from MATLAB, is used for estimation POPT is used to find the D-optimal design 100 D-optimal ABS were simulated for each scenario The relative percentage difference of the estimated parameter values from the true parameter values (%RE) were used to assess the performance of the 100 D-optimal ABS

13 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Study 1: Context Bridging study from adult patients to paediatric patients Dose schedule is based on mg/kg Paediatric patients parameter values were scaled allometrically Drug is a small molecule and given orally Bateman pharmacokinetic model

14 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Study 1 Bateman pharmacokinetic model

15 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Study 1 Bateman pharmacokinetic model Linear accumulation: CLVka CL41.560.100 V205.7100.10 ka11000.1

16 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Study 1

17 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Study 1 - %RE(Theta)

18 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Study 2: Context Bridging study from normal weight adult patients to obese adult patients Drug is a large molecule and given subcutaneously Delayed absorption in obese patients Transit compartment model

19 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Study 2 Transit compartment model

20 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Study 2 Transit compartment model CLVMTTN CL45.20.2000 V203000.200 MTT320000.20 N2200000

21 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Study 2

22 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Study 2 Linear accumulation Geometric accumulation Number of batches:

23 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Study 2 Geometric Accumulation - %RE(Theta)

24 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Study 2 Geometric Accumulation - %RE(Omega)

25 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Study 2 Geometric Accumulation with Mixture Model Estimation - %RE(Omega)

26 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Final Iteration - %RE(Theta)

27 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Discussion Both linear and geometric accumulation D-optimal ABS provides reasonable parameter estimates in the last iteration D-optimal ABS is a potentially useful method for bridging studies Need to test on batch size

28 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Acknowledgements Professor Stephen Duffull School of Pharmacy University of Otago PAGE Pharsight student sponsorship Modelling and Simulation lab members

29 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Study 2 Linear Accumulation - %RE(Theta)

30 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Study 2 Linear Accumulation - %RE(Omega)

31 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Study 2 Linear Accumulation with Mixture Model Estimation

32 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Study 2 Linear Accumulation with Mixture Model Estimation

33 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Study 2 Geometric Accumulation with Mixture Model Estimation

34 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Study 2 Geometric Accumulation with Mixture Model Estimation

35 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Study 2 3 Batches Linear - %RE(Theta)

36 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Study 2 3 Batches Linear - %RE(Omega)

37 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Study 2 3 Batches Geometric - %RE(Theta)

38 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Simulation Study 2 3 Batches Geometric - %RE(Omega)

39 Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand Final Iteration - %RE(Omega)

Download ppt "Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand D-optimal Adaptive Bridging Studies in Pharmacokinetics Lee-Kien Foo."

Similar presentations

The aim of this study was to characterise the population pharmacokinetics of tacrolimus in paediatric SCT recipients in the first year post-transplant;

The aim of this study was to characterise the population pharmacokinetics of tacrolimus in paediatric SCT recipients in the first year post-transplant;
Great Ormond Street Hospital for Children NHS Trust The School of Pharmacy UCL INSTITUTE OF CHILD HEALTH Centre for Paediatric Pharmacy Research Drug Development.

Great Ormond Street Hospital for Children NHS Trust The School of Pharmacy UCL INSTITUTE OF CHILD HEALTH Centre for Paediatric Pharmacy Research Drug Development.
Non compartmental analysis

Non compartmental analysis
Capecitabine: a pharmacokinetic model derived from its clinical use. Aldaz A. 1, Zufía L. 1, Bueno L. 2, Sayar O. 2 1 Pharmacy Department, University Hospital.

Capecitabine: a pharmacokinetic model derived from its clinical use. Aldaz A. 1, Zufía L. 1, Bueno L. 2, Sayar O. 2 1 Pharmacy Department, University Hospital.
American Conference on Pharmacometics –San Diego, CA; April 3-6 2011 Population PK modeling incorporating enzyme induction mechanism to guide the design.

American Conference on Pharmacometics –San Diego, CA; April Population PK modeling incorporating enzyme induction mechanism to guide the design.
Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.

Introduction to PKPD Modelling – Applications Joe Standing June 2012 UCL Institute of Child Health & Great Ormond Street Hospital for Children, London.
Dosage Regimen Design for Patients with Renal Insufficiency Pharmacy 732 Winter, 2001.

Dosage Regimen Design for Patients with Renal Insufficiency Pharmacy 732 Winter, 2001.
Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April 22, 2003 Pediatric Population Pharmacokinetics Study.

Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April 22, 2003 Pediatric Population Pharmacokinetics Study.
Issues in the Simulation and Analysis of QTc Interval Data Peter L. Bonate, PhD, FCP ILEX Oncology San Antonio, TX November 2003.

Issues in the Simulation and Analysis of QTc Interval Data Peter L. Bonate, PhD, FCP ILEX Oncology San Antonio, TX November 2003.
Purpose The National Physical Activity Guidelines Dimensions of Physical Activity Methods used to Measure Physical Activity Appropriate instruments for.

Purpose The National Physical Activity Guidelines Dimensions of Physical Activity Methods used to Measure Physical Activity Appropriate instruments for.
Figure 1. Diagnostic plots for propofol pharmacokinetics and effect (BIS) in morbidly obese patients including observations versus individual- predictions.

Figure 1. Diagnostic plots for propofol pharmacokinetics and effect (BIS) in morbidly obese patients including observations versus individual- predictions.
Classification of clinical trials

Classification of clinical trials
1 Clinical PK Optimal design and QT-prolongation detection in oncology studies Sylvain Fouliard & Marylore Chenel Department of clinical PK, Institut de.

1 Clinical PK Optimal design and QT-prolongation detection in oncology studies Sylvain Fouliard & Marylore Chenel Department of clinical PK, Institut de.
Predicting Paediatric Tobramycin Pharmacokinetics with Five Different Methods Joseph Standing, Elizabeth Greening, Victoria Holden, Susan Picton, Nicola.

Predicting Paediatric Tobramycin Pharmacokinetics with Five Different Methods Joseph Standing, Elizabeth Greening, Victoria Holden, Susan Picton, Nicola.
Modelling and Simulation Group, School of Pharmacy Pharmacokinetic design optimization in children and estimation of maturation parameters: example of.

Modelling and Simulation Group, School of Pharmacy Pharmacokinetic design optimization in children and estimation of maturation parameters: example of.
Background to Adaptive Design Nigel Stallard Professor of Medical Statistics Director of Health Sciences Research Institute Warwick Medical School

Background to Adaptive Design Nigel Stallard Professor of Medical Statistics Director of Health Sciences Research Institute Warwick Medical School
Chapter Nine Copyright © 2006 McGraw-Hill/Irwin Sampling: Theory, Designs and Issues in Marketing Research.

Chapter Nine Copyright © 2006 McGraw-Hill/Irwin Sampling: Theory, Designs and Issues in Marketing Research.
The use of the Chi-square test when observations are dependent by Austina S S Clark University of Otago, New Zealand.

The use of the Chi-square test when observations are dependent by Austina S S Clark University of Otago, New Zealand.
Analysis of Zidovudine pharmacokinetics to determine whether there is a genetic component to the variability and to determine the bioequivalence of seven.

Analysis of Zidovudine pharmacokinetics to determine whether there is a genetic component to the variability and to determine the bioequivalence of seven.
Division of Pharmacokinetics and Drug Therapy Department of Pharmaceutical Biosciences Optimizing Dosing Strategies for Defined Therapeutic Targets Mats.

Division of Pharmacokinetics and Drug Therapy Department of Pharmaceutical Biosciences Optimizing Dosing Strategies for Defined Therapeutic Targets Mats.

Similar presentations

Ads by Google